1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hunan Nucien Pharmaceutical Co. Ltd. Class A

Hunan Nucien Pharmaceutical Co. Ltd. Class A

SSSE:688189
5.92
CNY
-0.04
(-0.67%)
1.64BMarket Cap
Hunan Nucien Pharmaceutical Co. Ltd. Class A
SSE:688189
(Shanghai Stock Exchange)

Recent

price

5.92

P/E

ratio

- -

div

yld

0.04%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.87
0.98
3.41
4.93
7.84
5.27
3.57
2.39
0.92
0.52
- -
Revenue per Share
0.05
0.08
0.26
0.44
0.97
-1.17
-0.4
-0.08
-1.26
-0.5
- -
Basic EPS, GAAP
0.12
0.07
0.21
0.1
-2.43
-1.26
-1.03
0.67
-0.21
0.13
- -
Free Cash Flow per Basic Share
0.16
0.04
0.07
0.08
0.1
0.4
0.08
0.06
0.02
0.01
- -
Dividend per Share
0.37
0.88
1.14
1.62
5.82
5.07
4.79
4.71
3.41
2.86
2.84
Book Value per Share
0.06
0.27
0.58
1.11
5.42
4.3
4.08
3.99
2.61
2.1
2.05
Tangible Book Value per Share
318
355
206
206
131
140
196
274
274
274
272
Basic Weighted Avg Shares
278
348
701
1,014
1,029
738
699
655
252
142
- -
Sales/Revenue/Turnover
15.13
14.73
11.09
13.28
15.67
-11.89
9.24
6.35
-30.46
-55.13
- -
Operating Margin (%)
31
34
40
37
35
38
48
37
38
36
- -
Depreciation Expense
15
27
54
91
128
-163
-77
-21
-347
-137
- -
Net Income, GAAP
16.77
0.46
2.4
11.89
0.09
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
5.25
7.81
7.64
9.02
12.43
-22.11
-11.08
-3.25
-137.65
-96.46
- -
Profit Margin (%)
-124
-155
1
108
1,332
937
848
832
438
306
301
Working Capital
99
62
135
110
76
55
3
1
- -
- -
- -
LT Debt
171
202
265
357
1,619
1,392
1,296
1,274
878
712
710
Total Equity
- -
7.55
10.93
15.07
10
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
6.25
11.15
15.68
10.14
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
16.24
25.79
32.27
13.27
-10.93
-5.72
-1.63
-31.08
-15.92
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
10
10
60
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
274
274
274
Market Capitalization
2,187
2,099
1,641

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
400
376
442
Cash, Cash Equivalents & STI
302
278
347
Accounts Receivable, Net
36
30
15
Inventories
36
42
34
Total Current Liabilities
94
89
141
Payables & Accruals
- -
- -
- -
ST Debt
10
10
60
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-14.52%
-18.89%
Free Cash Flow
- -
-102.81%
-160.97%
Net Income, GAAP
- -
223.23%
-60.49%
Sales/Revenue/Turnover
- -
-29.01%
-43.62%
Total Cash Common Dividend
- -
25.5%
-48.2%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
136
79
36
1
252
2025
41
21
- -
59
142
2026
26
30
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
- -
-0.25
-1.09
-1.26
2025
-0.03
-0.12
- -
-0.25
-0.5
2026
-0.05
-0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.02
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hunan Nucien Pharmaceutical Co. Ltd. is a China-based pharmaceutical enterprise specializing in the research, development, manufacturing, and commercialization of chemical drugs, active pharmaceutical ingredients, and modern therapeutic preparations. Founded in 2006 and headquartered in Changsha, Hunan Province, the company operates primarily within the anti-infective, cardiovascular, cerebrovascular, anti-tumor, and chronic disease therapeutic areas, supplying public hospital networks, healthcare institutions, and retail pharmaceutical distributors throughout mainland China. The company offers an extensive portfolio of prescription drugs and formulations, including: anti-infective and antiviral agents, led by Peramivir Sodium Chloride Injection for influenza, Cefuroxime Axetil tablets and dispersible tablets, Cefazolin Sodium for injection, Cefodizime Sodium, and Azithromycin; cardiovascular and metabolic disease medications, comprising Captopril sustained-release tablets, Simvastatin tablets, Trimetazidine Hydrochloride, Metformin Hydrochloride sustained-release tablets, and Ginkgo Biloba extract preparations; gastrointestinal therapies, featuring Omeprazole enteric-coated capsules, Rabeprazole Sodium, and Mosapride Citrate; and anti-tumor therapeutics, specialty active pharmaceutical ingredients, and customized contract development and manufacturing services for third-party pharmaceutical partners. In recent major developments, the company has advanced its innovative drug pipeline by progressing clinical trials for next-generation oral anti-influenza candidates and small-molecule targeted anti-tumor compounds; expanded its commercial scale by securing key product listings under China's National Centralized Drug Procurement framework; adapted its corporate structure and strategic growth initiatives following restructuring within provincial state-owned asset platforms; and invested in the technical upgrade and capacity expansion of its intelligent manufacturing bases to enhance compliance and supply chain resilience.